Vanesa Quiroga

Vanesa Quiroga

Auto-generated profile, based on publicly available information

Vanesa Quiroga

Medical Oncology Department, Badalona-Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JAJoan Albanell
Joan Albanell
JPJosé Manuel Pérez-García
José Manuel Pérez-García
MGMiguel Juan Gil Gil
Miguel Juan Gil Gil
GCGiuseppe Curigliano
Giuseppe Curigliano
MRManuel Ruíz-Borrego
Manuel Ruíz-Borrego
ALANTONIO LLOMBART-CUSSAC
ANTONIO LLOMBART-CUSSAC
Purpose: To assess the efficacy and exploratory biomarkers of continuing palbociclib plus endocrine therapy (ET) beyond progression on prior palbociclib-based regimen in patients with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer (ABC). Patients and Methods: The multicenter, open-label, phase II BioPER trial included women who had experienced a progressive disease (PD) after having achieved clinical benefit on the immediately prior palbociclib plus ET regimen. Palbociclib (125 mg, 100 mg, or 75 mg daily orally for 3 weeks and 1 week off as per prior palbociclib-based regimen) plus ET of physician's choice were administered in 4-week cycles until PD or unacceptable toxicity. Coprimary endpoints were clinical benefit rate (CBR) and percentage of tumors with baseline loss of retinoblastoma (Rb) protein expression. Additional endpoints included safety and biomarker analysis. Results: Among 33 patients enrolled, CBR was 34.4% [95% confidence interval (CI), 18.6–53.2; P < 0.001] and 13.0% of tumors (95% CI, 5.2–27.5) showed loss of Rb protein expression, meeting both coprimary endpoints. Median progression-free survival was 2.6 months (95% CI, 1.8–6.7). No new safety signals were reported. A signature that included baseline mediators of therapeutic resistance to palbociclib and ET (low Rb score, high cyclin E1 score, ESR1 mutation) was independently associated with shorter median progression-free survival (HR, 22.0; 95% CI, 1.71–282.9; P = 0.018). Conclusions: Maintaining palbociclib after progression on prior palbociclib-based regimen seems to be a reasonable, investigational approach for selected patients. A composite biomarker signature predicts a subset of patients who may not derive a greater benefit from palbociclib rechallenge, warranting further validation in larger randomized controlled trials.

18 December 2019 in Breast Care
Verified
Journal Article
Closed access
PDF file
EFEudald Felip
Eudald Felip
LLLaia Llobera
Laia Llobera
CPClara Pérez-Mañá
Clara Pérez-Mañá
DQDavid Quintela
David Quintela
IGIgnacio Guasch
Ignacio Guasch
VQVanesa Quiroga
Vanesa Quiroga
Background: Palbociclib is a specific inhibitor of cyclin-dependent kinases 4 and 6 that is approved for the treatment of advanced or metastatic breast cancer patients. Despite a good toxicity profile in pivotal trials, where asymptomatic neutropenia was the main adverse effect, its wider use in clinical practice may show less prevalent but serious toxicities. Case Presentation: Here, we describe a case of pneumonitis due to palbocicblib. A 57-year-old female with breast cancer with bone metastasis presented dyspnea at rest 3 months after beginning treatment with palbociclib and letrozole. Palbociclib-induced pneumonitis was considered the most probable cause after ruling out all alternatives, and the patient was successfully treated with steroids and showed complete remission. Conclusions: In summary, we present a well-documented case report of pneumonitis related to palbociclib. However, the mechanism of toxicity is still unknown, and there are as yet no reliable biomarkers to predict toxicity with cyclin-dependent kinase 4/6 inhibitors. In this case report, we alert physicians about new drugs that can provoke old toxicities.

13 February 2020 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
BCBeatriz Oncology Cirauqui
Beatriz Oncology Cirauqui
TMTeresa Morán
Teresa Morán
AEAnna Estival
Anna Estival
VQVanesa Quiroga
Vanesa Quiroga
OEOlatz Etxaniz
Olatz Etxaniz
MMMireia Margelí
Mireia Margelí
Germline mutations in TP53, a tumor suppressor gene, are involved in the development of Li-Fraumeni syndrome, a rare disorder that predisposes carriers to multiple tumors. TP53 mutations have been associated with resistance to treatment and poor prognosis. A young female with the pathogenic germline TP53 mutation c.844C > T (p.R282W) was diagnosed with two metachronous breast tumors, one HER2-negative and the other HER2-positive. She was later diagnosed with synchronous glioblastoma, epidermal growth factor receptor-mutated lung adenocarcinoma, and HER2-negative breast cancer metastases. The patient was treated with local therapies, including brain surgery and radiotherapy, lung surgery, and a bilateral mastectomy, as well as with targeted systemic treatment. She proved to be highly sensitive to systemic therapy, and 13 years after the initial diagnosis of breast cancer and 6 years after the diagnosis of the two new primary tumors and recurrence of a prior cancer, she is alive with an excellent performance status. This surprising positive evolution may well be partly due to the pronged multidisciplinary approach to managing her disease and her extraordinary response to treatment: the lung adenocarcinoma showed excellent response to erlotinib; the breast cancer responded extremely well to eribulin and pegylated liposomal doxorubicin; and the glioblastoma has remained in response to surgery and radiotherapy. Despite harboring a TP53 mutation and having multiple tumors, this patient has shown an unexpectedly favorable evolution. The coordinated participation of a multidisciplinary team and the patient’s own extraordinarily high sensitivity to systemic treatment played a major role in this evolution.

23 February 2019 in Oncology Research and Treatment
Verified
Journal Article
Closed access
PDF file
TMTeresa Moran
Teresa Moran
VQVanesa Quiroga
Vanesa Quiroga
BCBeatriz Cirauqui
Beatriz Cirauqui
LVLaia Vila
Laia Vila
MGMaria Gil-Moreno
Maria Gil-Moreno
RRRafael Rosell
Rafael Rosell
Background: Second primary malignancies (SPM) in the lung are not common in breast cancer (BC) patients. EGFR-mutant lung cancer (LC) is a separate molecular subset, and the co-existence of EGFR-mutant LC and BC has not been explored. We hypothesized that EGFR-mutant LC patients could have higher rates of primary BC than those with EGFR-wild type (WT). Methods: We collected data on clinical and molecular characteristics and outcomes of female patients with LC and a previous or simultaneous history of primary BC treated in our hospital from 2008 to 2014. Results: Data on treatment, follow-up, and EGFR mutation status were available for 356 patients. 17.7% (11/62) of patients with EGFR mutations had BC, compared to 1.02% (3/294) of EGFR-WT patients (p < 0.001). Both tumors were metachronous in 81.8%, with LC diagnosed 9 years after the diagnosis of BC. 5 of the 6 (83.3%) BC patients treated with radiotherapy developed LC in an area within the radiation field. No EGFR mutations were detected in BC tissue and no HER2 expression was detected in LC samples. Conclusion: SPM in the lung and breast occur more frequently among EGFR-mutant compared to EGFR-WT LC patients. Radiotherapy for BC may increase the risk of developing primary LC.

1 December 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
Mafalda OliveiraMafalda Oliveira
Mafalda Oliveira
ECEva Maria Ciruelos
Eva Maria Ciruelos
GVGuillermo Villacampa
Guillermo Villacampa
SMSerafin Morales
Serafin Morales
JSJavier Salvador-Bofill
Javier Salvador-Bofill
CMCristina Saura Manich
Cristina Saura Manich
Purpose: The aim of this study was to evaluate the safety and feasibility of ipatasertib combined with trastuzumab and pertuzumab (HP) as maintenance therapy after first-line treatment in patients with HER2-positive metastatic breast cancer harboring PIK3CA mutations (PIK3CAmut). Patients and Methods: This prospective, multicenter, single-arm, phase Ib study evaluated the safety and preliminary efficacy of ipatasertib, an AKT inhibitor, combined with HP, with or without endocrine therapy as maintainance therapy, in patients with unresectable locally advanced or metastatic PIK3CAmut, HER2-positive breast cancer following first-line induction chemotherapy and HP. Results: Seventeen patients were enrolled, with a median follow-up of 27.7 months. During the dose-selection phase, ipatasertib at 400 mg daily (21 days on and 7 days off) with standard HP was established as the recommended phase II dosage. This decision was based on the absence of dose-limiting toxicities in the first six patients treated at this dosage during the initial 28-day cycle, which constituted the primary endpoint. Grade 3 treatment-related adverse events (TRAE) occurred in seven patients (41.2%), most commonly diarrhea and nausea. Two (11.8%) reported four serious TRAE (diarrhea, vomiting, ischemic stroke, and pneumonitis, one case each) related to ipatasertib, from which they recovered. The confirmed overall response rate was 31.1% [95% confidence interval (CI), 12.1%–58.5%], clinical benefit rate 84.6% (95% CI, 53.7%–97.3%), and median progression-free survival 16.4 months (95% CI, 9.4–NR); 47.3% of patients were progression free at 18 months. Conclusions: These results support ipatasertib plus HP as a safe and promising maintenance strategy for HER2-positive breast tumors harboring PIK3CAmut.

15 February 2021 in Cancer Research
Verified
Journal Article
Closed access
APAleix Prat
Aleix Prat
JGJoaquin Gavilá
Joaquin Gavilá
SPSonia Pernas
Sonia Pernas
JCJosefina Cruz
Josefina Cruz
CMCristina Saura Manich
Cristina Saura Manich
PVPatricia Villagrasa
Patricia Villagrasa
Background: Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 15-20% of breast cancers (BC). At the same time, HER2-low tumors (immunohistochemistry 1+ or 2+ with no gene amplification) comprise ~50% of all BC. DS-8201a is an anti-HER2 antibody drug conjugate that has shown very promising response rates both in HER2+ and HER2low BC. However, not all patients respond or benefit to the same extend. Thus, there is a need to identify predictive biomarkers. Here, we hypothesize that by performing several molecular studies in both tissue and plasma samples of those patients participating in the pivotal DESTINY-Breast trials, we will shed more light about the molecular features of HER2+ BC and better characterized the patient population according to their benefit from this promising new anti-HER2 agent. Methods: HER2-PREDICT is a multi-center, observational study within the biomarker program of SOLTI group, which will include patients who will participate, are participating or previously participated in the Daiichi Sankyo INC sponsored phase III trials: DS8201-A-U301 (NCT03523585), -U302 (NCT03529110) and -U303 (NCT03734029). Patients with HER2-positive or HER2-low unresectable and/or metastatic breast cancer may be included in SOLTI-1804 HER2-PREDICT study if randomized to the DS-8201a arm. All patients need to consent for obtaining a fresh tumor biopsy or donating an archival metastatic biopsy. Primary tumors are allowed under SOLTI acceptance. Additionally, patients included before initiating DS-8201a therapy will provide blood samples for biomarker analyses on Cycle 1 Day 1 (C1D1), C2D1 and end of treatment. The primary objectives are (1) to identify an optimal ERBB2 mRNA cut-off point predictive of Ds-8201a response and (2) to evaluate the correlation of baseline ERBB2 mRNA levels (as a continuous variable) with overall response rate (ORR) in the Ds-8201a-treated cohorts. Secondary objectives includes: to evaluate the association of ERBB2 mRNA levels, PAM50 intrinsic subtypes and immune-related genes with ORR, progression-free survival and overall survival; to design a new gene expression signature predictive of Ds-8201a benefit; to correlate early changes in ctDNA with Ds-8201a benefit and to identify acquired somatic mutations of resistance to DS8201a upon progression in plasma samples. Collection of tumor biopsies is an essential part of this study. Pathological analysis includes hematoxylin and eosin (H&E) staining, identification of areas with greater amount of tumor cells and determination of their tumor cell percentage. RNA will be isolated and analyzed at the nCounter (Nanostring Technologies). Molecular intrinsic subtypes will be identified by a research-based version of PAM50. Furthermore, we aim to evaluate 771 additional genes (+5 housekeeping genes) that encompass important genomic signatures and individual genes of importance for breast cancer by means of the nCounter®Breast Cancer 360 Panel. Somatic mutations in PIK3CA, TP53, and additional genes (e.g., GATA3 and ERBB2) will be identified using next-generation sequencing (NGS). Also, a comprehensive NGS gene panel will be performed under the Ion Torrent or Illumina platforms to DNA extracted from FFPE tumor blocks and to circulating tumor DNA (ctDNA) in plasma samples. Current status: Since December 13th, 2019, a total of 10 patients have been included, 5 of them with blood samples. As of today, 13 out of 15 Spanish sites are recruiting patients. Clinical trial identification: NCT04257162 Citation Format: Aleix Prat, Joaquin Gavilá, Sonia Pernas, Josefina Cruz, Cristina Saura, Esteban Nogales, Maria Bermejo, Javier Salvador Bofill, Vanesa Quiroga, Laura Garcia-Estévez, Serafin Morales, Sonia Servitja, Rubén del Toro, Patricia Galván, Núria Chic, Débora Martinez, Fara Brasó-Maristany, Jordi Canes, Laia Paré, Juan M Ferrero-Cafiero, Patricia Villagrasa. Solti-1804 HER2-PREDICT: A biomarker research study of DS8201-A-U301 -U302 and -U303 trials [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr OT-03-07.